Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Britain Courts Anthropic Amid US Defense Department Dispute 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
BURLINGTON, Mass., July 03, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will hold an Investor and Analyst Day on Monday, July 10, 2017. Flexion executives will discuss plans for commercializing Zilretta™ (FX006), the company’s lead investigational product candidate for the treatment of osteoarthritis knee pain. Management will also provide an update on the company’s pipeline, and they will be joined by two medical experts who will present important clinical perspectives on Zilretta.
Event Details
Date: Monday, July 10, 2017
Time: 10:00 a.m. – 12:00 p.m. EDT
The presentation will be accessible via live webcast at: http://edge.media-server.com/m/p/a5pnvdm8. A replay will also be available on the company’s website.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate, Zilretta, is being investigated for its potential to provide improved analgesia for the millions of U.S. patients who receive intra-articular injections for OA related knee pain annually.
Corporate Contact: Scott Young Sr. Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 [email protected]
